Collaboration. Acceleration. Results.      1 877 TO FIX MS
Myelin Repair Foundation Home Page Donate to Myelin Repair Foundation
Print

Board and Advisors

Board of Directors

Scientific Advisory Board (SAB)

Current Members

Former Members

  • Joe Davie, M.D., Ph.D., Biogen, Inc. (Retired)

Drug Discovery Advisory Board (DDAB)

Clinical Advisory Board (CAB)

Board of Directors

Andy Cates, Managing Member, Value Acquisition Fund

Andy Cates is the Managing Member of Value Acquisition Fund and the General Partner of RVC USA, LP (a related company). Cates began his real estate career in Dallas, Texas, where he worked as an Analyst in Trammell Crow Company's Capital Markets Group, and became an Associate for Crow Family Holdings. In 1996, Cates was a founding partner of Viceroy Investments, LLC which has been the General Partner in over $120 million of commercial real estate transactions.

In 1999, Cates developed the Soulsville Revitalization Project as its Project Developer and Board Chairman, a $30 million nonprofit project includes the Stax Museum of American Soul Music and The Stax Music Academy (www.soulsvillefoundation.org).

Cates earned a Bachelor of Business Administration (Finance) degree from the University of Texas at Austin. In addition to serving as a Board Member of the Myelin Repair Foundation, Cates serves on the boards of the Pioneer Natural Resources (PXD: NYSE), the Soulsville Foundation, Soulsville Charter School, and Grizzlies Prep Charter School.

- Back to top -

James Gidwitz, Chairman of the Board and Chief Executive Officer, Continental Materials Corporation

Jim Gidwitz has held various positions at Continental Materials Corporation since 1978. Prior to his experience in business, Mr. Gidwitz served in the U.S. Air Force where his final rank was Sergeant. Co-founder and Director of the Jamestown Foundation, Mr. Gidwitz continues to be an active board member. Additionally, Mr. Gidwitz is a member of the Board of Trustees of the Hotchkiss School and a member of the Board of Overseers of the Hoover Institution. Mr. Gidwitz attended the Hotchkiss School and received a B.A. in Political Science from Stanford University.

- Back to top -

Scott Johnson, President and Founder, Myelin Repair Foundation

See bio under Myelin Repair Foundation Management

- Back to top -

Casey McGlynn, Partner, Wilson Sonsini Goodrich & Rosati

Casey McGlynn is an attorney who specializes in the fields of corporate law, securities, and mergers and acquisitions. Mr. McGlynn has spent his career assisting entrepreneurs in organizing, building and financing their businesses. He received a B.S. in Economics in 1975 and a J.D. in 1978 from Santa Clara University. He was admitted to the Bar in California in 1978. Mr. McGlynn joined the law firm of Wilson Sonsini Goodrich & Rosati upon his graduation from law school when the firm had only 14 attorneys. Today the firm has more than 550 attorneys. Mr. McGlynn is a member of the Executive Committee and has served on the Compensation and Nomination Committees of the firm. He is a frequent lecturer and writer, focusing on financing issues facing young companies. He is also a founding member of the American Heart Association Roundtable and the American Diabetes Association Leaders Forum, and assists these organizations in their fund-raising activities.

- Back to top -

Siddharth N. “Bobby” Mehta, TransUnion Board Member, Strategic Advisor

Siddharth N. (Bobby) Mehta is a director and the former President and Chief Executive Officer of Transunion. He joined the Company in August 2007 and served as the President & Chief Executive Officer until December 31, 2012. Prior to joining TransUnion, Mr. Mehta served as Chairman and CEO of HSBC Finance Corporation. He has also held positions as Senior Vice President at The Boston Consulting Group (BCG) and Vice President of Citicorp's information business division. Mr. Mehta received a B.A. in Economics from the London School of Economics, and a M.B.A. from the University of Chicago.

- Back to top -

Sharon Wienbar, Managing Director, Scale Venture Partners

Sharon Wienbar invests in mobile, Internet and enterprise software companies at Scale Venture Partners, which she joined in 2001. She sits on the boards of Bellamax, Biz360, Facetime Communications, Glue Mobile, Merchant Circle and Reply.com. Sharon holds a B.A. and a M.A. in Engineering from Harvard University, and an M.B.A. from the Stanford Graduate School of Business.

- Back to top -

Scientific Advisory Board (SAB)

Stephen Freedman, Ph.D., Gladstone Institute (Also a member of theDrug Discovery Advisory Board)

Dr. Stephen Freedman is Director of the Gladstone Center for Translational Research (GCTR) and Vice President for Corporate Liaison and Ventures at the Gladstone Institutes. Dr. Stephen Freedman has more than 25 years of experience in the pharmaceutical industry including senior positions at Merck and Co. where he was a senior member of their CNS research group, and for Elan Pharmaceuticals as Sr. Vice President, Head of Global Research. He has interests in a number of therapeutic areas including neurology, psychiatry, pain, inflammation and a number of associated autoimmune diseases including multiple sclerosis, asthma, RA and IBD. During his association with Merck and Elan, Dr. Freedman worked on more than a dozen small molecules and biologics entering clinical development. He is an author on nearly 100 research publications and is an inventor on a number of patents in these therapeutic areas.

- Back to top -

Stephen L. Hauser, M.D., University of California, San Francisco

Dr. Hauser is the Robert A. Fishman Distinguished Professor and Chair of the Department of Neurology at UCSF. He is a graduate of MIT (Phi Beta Kappa) and Harvard Medical School (Magna Cum Laude). He trained in internal medicine at the New York Hospital–Cornell Medical Center, in neurology at the Massachusetts General Hospital (MGH), and in immunology at Harvard Medical School and the Institute Pasteur in Paris, France, and was a faculty member at Harvard Medical School before moving to UCSF.

A neuroimmunologist, Dr. Hauser’s research has advanced our understanding of the genetic basis, immune mechanisms, and treatment of multiple sclerosis. Dr. Hauser is a fellow of the American Academy of Arts and Sciences and the American Academy of Physicians, a member of the Institute of Medicine of the National Academy of Sciences (former Chair of Committee on Gulf War and Health Outcomes and current Chair of Committee on Long Term Effects of Blast Exposure), an editor of the textbook Harrison’s Principles of Internal Medicine, and editor-in-chief of Annals of Neurology. He is a former President of the American Neurological Association and President of the Medical Staff at UCSF. He also serves on several scientific advisory boards for nonprofit organizations. Dr. Hauser has received numerous awards and honors for his work, including the Jacob Javits Neuroscience Investigator Award and the John Dystel Prize for Multiple Sclerosis Research. In April 2010 Dr. Hauser was appointed by President Obama to the Presidential Commission for the Study of Bioethical Issues charged with advising the President on issues that may emerge from advances in biomedicine and related areas of science and technology.

- Back to top -

Samuel Ludwin, M.D., Queen's University Kingston and Kingston General Hospital

Dr. Samuel Ludwin attended medical school at the University of Witwatersrand, Johannesburg, South Africa, and followed this with residency and fellowship training in Pathology and then Neuropathology at Stanford University in California. He moved to Canada after his fellowship to take an academic position at Queen’s University and Kingston General Hospital in Kingston Ontario where he is now a Professor of Pathology (Neuropathology). He has been at Queen’s University and Kingston General Hospital since then, apart from a period of time where he served as Chairman of the Department of Pathology at the University of Western Ontario in London, Ontario. Dr. Ludwin also recently served as Associate Dean (Research) in the Faculty of Health Sciences, Queen’s University and Vice-President (Research Development) of Kingston General and Hotel Dieu Hospitals. Dr. Ludwin is the Past-Chairman of the Medical Advisory Board of the Multiple Sclerosis Society of Canada, and has served on the Research Development Committee of the National Multiple Sclerosis Society of the United States. He has also been President of the International Society of Neuropathology.

Dr. Ludwin has had a long-standing research and clinical interest in multiple sclerosis. His research work has centered around mechanisms of remyelination and demyelination as well as oligodendrocyte and astrocyte behavior and the translation of these basic observations into clinical studies on multiple sclerosis.

- Back to top -

Henry F. McFarland, M.D., National Institutes of Neurological Disorders and Stroke (Retired)

Dr. Henry F. McFarland M.D. is the retired Chief of the Neuroimmunology Branch of the National Institute of Neurological Disorders and Stroke.

Dr. McFarland received his B.A. degree from the University of Arizona and his M.D. in 1966 from the University of Colorado. Following a residency in neurology at Thomas Jefferson University, Dr. McFarland did postdoctoral research in neurovirology at Johns Hopkins School of Medicine and in immunology at University College London, before returning to Hopkins as a neurologist. In 1994, Dr. McFarland became Chief of the Neuroimmunology Branch of the NINDS. He retired from this position in 2010.

- Back to top -

Martin Raff, M.D., University College London

Dr. Martin Raff was born and educated in Montreal. He received his B.S. and M.D. degrees at McGill University and did a residency in medicine at the Royal Victoria Hospital in Montreal and in neurology at the Massachusetts General Hospital in Boston. He did postdoctoral training in immunology at the National Institute for Medical Research in London, after which he moved to University College London, where he has been a Professor of Biology since 1979. He is currently at the Medical Research Council Laboratory for Molecular Cell Biology at University College London. His research has been in immunology, cell biology, and developmental neurobiology. He is a Fellow of the Royal Society and the Academia Europaea, a founding member of the Academy of Medical Sciences, a member of the European Molecular Biology Organisation, and a foreign member of the American Academy of Arts and Sciences and the National Academy of Sciences. He was president of the British Society of Cell Biology from 1991 to 1995. He is one of the original co-authors of two widely used cell biology textbooks — Molecular Biology of the Cell and Essential Cell Biology. Dr. Raff is Professor Emeritus of Biology at University College London.

- Back to top -

Louis Reichardt, Ph.D., University of California, San Francisco

Dr. Louis Reichardt is Director of the Simons Foundation Autism Research Initiative (SFAR) and Professor emeritus of Physiology and of Biochemistry and Biophysics (on recall), and former Director of the Herbert W. Boyer Program in Biological Sciences and the Neuroscience Graduate Program at the University of California, San Francisco.

Dr. Reichardt received his Ph.D. in biochemistry at Stanford University for work on control of gene expression by the phage λ. He entered the field of neurobiology as a postdoctoral Fellow at Harvard University where he studied factors that regulate the transmitter phenotype of neurons. Dr. Reichardt’s honors include a McKnight Scholars Award, a Sloan Award, and a Guggenheim fellowship. He is a Fellow of the American Association for the Advancement of Science.

- Back to top -

Arnon Rosenthal, Ph.D., Alector LLC.

Arnon Rosenthal received his Ph.D. from the Hebrew University Jerusalem, Israel and then conducted a post-doctoral fellowship at Genentech, Inc. He was appointed to a scientist position at Genentech Inc. in 1988, was promoted to a senior scientist in 1992 and then to a staff scientist and a permanent member of Genentech Research Review Committee in 1996.

In 2001 Dr. Rosenthal co-founded and became the president, board member and CSO of Rinat Neuroscience, a privately-held company that discovered and developed novel medicines for neurodegenerative, neuroendocrine and pain disorders. The company was acquired by Pfizer with several drugs in clinical development including Tanezumab which is currently in Phase III for multiple pain indications, PF-04360365 which entered Phase II for Alzheimer’s disease and RN-307 which entered the clinic for migraine.

He is a co-founder and board chair of Annexon pharmaceuticals since 2011, and is also a co-founder, President, and CEO of Alector LLC, a privately held Biotechnology company focused on the discovery and envelopment of novel therapy for Alzheimer's disease and other forms of dementia since 2013.

Dr. Rosenthal is a visiting professor at the department of Anatomy UCSF and a member of the scientific advisory board of the Simons Foundation Autism Research Initiative in addition to the Myelin Repair Foundation. He has co-authored 108 scientific publications, and over 380 issued patents and applications.

- Back to top -

Lee Rubin, Ph.D., Harvard Stem Cell Institute, Department of Stem Cell & Regenerative Biology

Dr. Lee Rubin received his Ph.D. in Neuroscience from The Rockefeller University and completed postdoctoral fellowships in Pharmacology from Harvard Medical School and in Neurobiology from Stanford University School of Medicine. He has worked both in academia and in industry. Notably, at Athena Neurosciences (now Elan Pharmaceuticals), he initiated a project that lead to the discovery of an antibody that blocks lymphocyte trafficking across the BBB. This work culminated in the development of an anti-integrin antibody, now known as Tysabri, which has been approved for treatment of multiple sclerosis. Subsequently, he became Chief Scientific Officer of Ontogeny, Inc (now Curis, Inc), a biotechnology company in Cambridge, MA, founded by Dr. Douglas Melton. Dr. Rubin's work there centered on the hedgehog (Hh) pathway and its involvement in cancer and neurodegenerative disease. Potent small molecule Hh antagonists were identified and partnered with Genentech where they were modified chemically, and, one, Erivedge, was approved as an oral treatment for invasive basal cell carcinoma. Numerous other phase II solid tumor studies are currently underway.

Dr. Rubin is currently Professor of Stem Cell and Regenerative Biology at Harvard University and Director of Translational Medicine at the Harvard Stem Cell Institute. Much of his effort is devoted to identifying therapeutics for orphan neural disorders such as Spinal Muscular Atrophy and Amyotrophic Lateral Sclerosis, using new kinds of stem cell-based screens. His lab also explores different chemical biology approaches for manipulating cell fate. Some of this work has been published recently in Cell, Cell Stem Cell, Nature Chemical Biology, Developmental Biology and Science.

- Back to top -

Hartmut Wekerle, M.D., Ph.D., Max Planck Institute of Neurobiology

Hartmut Wekerle was born in 1944 in Waldshut, studied medicine at the University of Freiburg. As a post-doctoral researcher, he worked at the Weizmann Institute of Science (Israel) and the Max Planck Institute for Immunobiology in Freiburg. Afterwards, he led the Research Group for Multiple Sclerosis of the Max-Planck-Society at the University Hospital of the University of Würzburg. In 1988, he was appointed director at the Max Planck Institute for Neurobiology. Since his retirement as director (2012), he holds a Hertie Foundation Senior Professorship and leads an Extended Emeritus Group at the Max-Planck-Institute.

Hartmut Wekerle’s scientific research is focused on the mechanisms initiating and driving diseases which arise autoimmune attacks against the nervous system, most importantly multiple sclerosis and its experimental models. Wekerle’s work led the identification of brain reactive autoimmune T lymphocytes in the immune system. Most recently, he identified the commensal bacterial gut flora as a factor triggering pathogenic potential of these immune cells.   He develops and uses new imaging approaches to detail the mechanisms of autoimmune T cell migration into the brain.

Wekerle received several awards including the Jung Prize, Zülch Prize, Koetser Prize, Charcot Award (MS International Federation), Louis D. Grand Prix (Institut de France), and a Koselleck Award (Deutsche Forschungsgemeinschaft). He holds an Honorary Professorship of the University of Munich and an Honorary Doctorate of the University of Hamburg. He is a member of the German Academy of Science (Leopoldina).

- Back to top -

Gary Westbrook, M.D., Oregon Health Sciences University

Dr. Gary Westbrook is a Senior Scientist and Co-Director of the Vollum Institute in Portland, OR. He concurrently holds an appointment as the Dixon Professor of Neurology in the School of Medicine at Oregon Health & Science University. Dr. Westbrook received an M.D. from Case Western Reserve University in Cleveland in 1976 after undergraduate work in biology and graduate study in biomedical engineering. He was an intern and resident at Mt. Auburn Hospital in Boston and at the Washington University School of Medicine in St. Louis. After clinical training in Internal Medicine and Neurology, he spent six years at the National Institutes of Health before moving to the Vollum Institute in 1987. Dr. Westbrook has been the recipient of Javits and MERIT awards from NIH for his research on synaptic transmission in the central nervous system. He is a former Editor-in-Chief of the Journal of Neuroscience and former member of the Advisory Council of the National Institute of Neurological Disorders and Stroke. He is a fellow of the American Academy of Arts and Sciences and was elected to the Institute of Medicine of the National Academies in 2008.

- Back to top -

Drug Discovery Advisory Board (DDAB)

Stephen Freedman, Ph.D., Consultant

Dr. Stephen Freedman is Director of the Gladstone Center for Translational Research (GCTR) and Vice President for Corporate Liaison and Ventures at the Gladstone Institutes. Dr. Stephen Freedman has more than 25 years of experience in the pharmaceutical industry including senior positions at Merck and Co. where he was a senior member of their CNS research group, and for Elan Pharmaceuticals as Sr. Vice President, Head of Global Research. He has interests in a number of therapeutic areas including neurology, psychiatry, pain, inflammation and a number of associated autoimmune diseases including multiple sclerosis, asthma, RA and IBD. During his association with Merck and Elan, Dr. Freedman worked on more than a dozen small molecules and biologics entering clinical development. He is an author on nearly 100 research publications and is an inventor on a number of patents in these therapeutic areas.

- Back to top -

David R. Fitzpatrick, Biotech Clarity Consulting

David R. Fitzpatrick, Biotech Clarity Consulting Owner of Biotech Clarity Consulting, Dr. David R. Fitzpatrick has more than 30 years of experience in research and development that includes consulting with venture capital, startup biotech, listed biopharma and big pharma clients in the U.S., Canada, UK, China and Australia. Dr. Fitzpatrick held senior positions at Immunex and Amgen where his group helped advance multiple projects into phase I clinical trials, and more than a dozen other projects toward clinical development, for diseases such as asthma, atopic dermatitis, cancer, hepatitis, inflammatory bowel disease, lung fibrosis, lupus, multiple sclerosis, psoriasis and rheumatoid arthritis. He also served on the Licensing, Extramural Research, Portfolio Review, Patent Review, R&D Training and R&D Strategy Committees.

Dr. Fitzpatrick has an international reputation for his research in epigenetics, T-cell immunology and cytokine biology, in the context of transplantation, autoimmunity, cancer and infectious diseases. He is an author on more than 70 publications, an associate editor or reviewer for more than 15 journals, and an active member of a number of scientific associations and advisory boards.

- Back to top -

Christopher Lipinski, Ph.D., Consultant

Dr. Christopher Lipinski was Adjunct Senior Research Fellow at the Pfizer Global R&D Groton CT Laboratories until his retirement in June 2002 and is now a Scientific Advisor to Melior Discovery, a drug repurposing startup. He is a member of the American Chemical Society (ACS), AAPS, Society of Biomolecular Sciences (SBS) and EUFEPS. A consultant on drug-like properties, he serves on numerous scientific advisory and journal editorial boards.

Dr. Lipinski is the author of the “rule of five” a widely-used filter to select for acceptable drug oral absorption. In 2006 he received an honorary law degree from the University of Dundee and is also the 2006 Society for Biomolecular Sciences Achievement Award winner. In 2005 he was the American Chemical Society winner of the E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances and in 2004 the winner of the Division of Medicinal Chemistry Award of the ACS Division of Medicinal Chemistry. He is an adjunct faculty member at the University of Massachusetts, Amherst and has published and presented more than 225 journal articles and invited presentations and issued 17 U.S. patents.

- Back to top -

Michael A. Pleiss, Ph.D., Consultant

Michael A. Pleiss, Ph.D. is a medicinal chemist with more than 25 years of industrial experience in pharmaceutical research and a proven track record of novel small molecule drugs in several therapeutic areas. Compounds that he has advanced into clinical trials or that are in predevelopment represent novel therapeutics for asthma, rheumatoid arthritis, multiple sclerosis, neuropathic pain and Alzheimer’s disease. Dr. Pleiss is currently a private consultant with expertise in all aspects of drug design and development through Phase 1, including medicinal chemistry and outsourcing, computational chemistry, patent construction and breaking, DMPK, and CMC. Dr. Pleiss was most recently Vice President of Chemistry and Drug Metabolism & Pharmacokinetics (DMPK) at Elan Pharmaceuticals. Dr. Pleiss has also held positions at Genentech and Syntex prior to joining Athena Neurosciences / Elan Pharmaceuticals.

- Back to top -

Mark Scheideler, Ph.D., Consultant

Dr. Mark Scheideler recently served in the government as Senior Scientific Officer at the National Institute of Neurological Disorders and Stroke (Bethesda, MD, USA), working to develop the Roadmap Molecular Libraries and CTSA Initiatives. He came to the NIH in mid-2005 with twelve years of international therapy development experience, including roles as SVP at MDS Proteomics, Head of Neurobiology Research at SmithKline Beecham (then GSK), and Principal Scientist at Novo Nordisk. Dr. Scheideler has held academic posts as Research Assistant Professor of Neurological Surgery at Albert Einstein College of Medicine and Research Fellow at Duke University Medical Center. Dr. Scheideler earned a Ph.D. in Biochemistry from the University of Chicago, a B.A. in Biochemistry & Molecular Biology from Northwestern University and a certificate in Finance & Accounting from the Wharton School.

- Back to top -

Ted Yednock, Ph.D., Consultant

Dr. Yednock is a scientific advisor to several companies and foundations focused on neurodegeneration, inflammation and oncology. He was previously Chief Scientific Officer for Prothena Biosciences, Head of Research for Elan Pharmaceuticals and a scientist at Athena Neurosciences (which was purchased by Elan). While at Athena, Dr. Yednock initiated research on multiple sclerosis that led to the development of Tysabri®, a marketed monoclonal antibody with 2012 sales exceeding $1.5 billion. In addition to his work in multiple sclerosis, Dr. Yednock has contributed to the invention or progression of more than a dozen drugs in the areas of rheumatoid arthritis, Crohn’s disease, pain, Alzheimer’s disease and Parkinson's disease. He has been involved in collaborations with Biogen-Idec, Wyeth/Genetics Institute, Johnson & Johnson, Janssen Alzheimer's Immunotherapy, the Michael J. Fox Foundation, the Alzheimer’s Drug Discovery Foundation and the Parkinson’s Institute, among many others. Dr. Yednock earned his B.S. in Biology and Chemistry from the University of Illinois and his Ph.D. in Anatomy and Cell Biology from UCSF, where he also completed postdoctoral fellowships in Cell Biology and Immunology.

- Back to top -

Clinical Advisory Board (CAB)

Peter Calabresi, M.D., Director of the Multiple Sclerosis Center at Johns Hopkins.

Dr. Peter Calabresi received his undergraduate degree from Yale University and his medical degree from Brown University. He then completed an internship and residency training in internal medicine at Strong Memorial Hospital. He went on to complete a fellowship in Neuroimmunology at the National Institutes of Health.

Now a Professor of Neurology at Johns Hopkins, Dr. Calabresi serves as the Director of the Multiple Sclerosis Center, focusing on the diagnosis and management of MS. He is the principal investigator on several clinical trials and oversees research projects seeking to create new anti-inflammatory and neuroprotective therapies for MS.

Dr. Calabresi’s specific laboratory research interest lies in understanding the mechanisms of T lymphocyte migration into the brain and spinal cord. He has published numerous articles on the adhesion molecules and chemokine receptors responsible for T cell homing to the brain in MS, and was involved in the early testing of natalizumab (Tysabri).  He also has funding from the National Institutes of Health to study a potassium channel, Kv1.3, which is specifically and highly expressed on chronically activated immune cells in the blood and brains of people with MS.

Dr. Calabresi’s group was awarded a five year Tissue Repair MS center grant from the National MS Society to study mechanisms of neurodegeneration and strategies for neuroprotection in MS. This has fueled extensive collaborations with neuroscientists at Hopkins utilizing a variety of transgenic and knockout mice to examine the mechanisms of myelin and axon pathology that may occur in MS. Im addition, his group collaborates with imaging experts at Hopkins and NIH utilizing cutting edge brain and spinal cord MRI technologies such as diffusion tensor imaging as well as optical coherence tomography (OCT), which allow assessments of axonal integrity.

- Back to top -

Prof. Dr. Roland Martin, Institute for Neuroimmunology and Clinical Multiple Sclerosis Research

Prof. Dr. Martin is the Director of INIMS (Institute for Neuroimmunology and Clinical Multiple Sclerosis Research), Center for Molecular Neurobiology in Hamburg, Germany. His research interests include the development and Phase I/II testing of novel therapies for MS, among them antigen-specific tolerization strategies and cell-based therapies with hematopoietic stem cells and mesenchymal stem cells. He has served as Principal Investigator on multiple Phase IIa clinical trials, and is currently heading the Establish Tolerance in MS (ETIMS) trial, a cell therapy for tolerization with peptide-pulsed, fixed antigen presenting cells (Phase I/IIa first-in-man). His additional research interests include MRI-, clinical and molecular biomarkers in MS; disease heterogeneity in MS; cellular immunology of MS (in particular, CD4+ and CD8+ T cell subsets); and the functional characterization of risk-conferring genes in MS.

- Back to top -

Henry F. McFarland, M.D., National Institutes of Neurological Disorders and Stroke (Retired)

Dr. Henry F. McFarland M.D. is the retired Chief of the Neuroimmunology Branch of the National Institute of Neurological Disorders and Stroke.

Dr. McFarland received his B.A. degree from the University of Arizona and his M.D. in 1966 from the University of Colorado. Following a residency in neurology at Thomas Jefferson University, Dr. McFarland did postdoctoral research in neurovirology at Johns Hopkins School of Medicine and in immunology at University College London, before returning to Hopkins as a neurologist. In 1994, Dr. McFarland became Chief of the Neuroimmunology Branch of the NINDS. He retired from this position in 2010.

- Back to top -

Alfred Sandrock, M.D., Ph.D., Biogen Idec

Alfred W. Sandrock Jr., M.D., Ph.D., is Chief Medical Officer and Senior Vice President of Development Sciences at Biogen Idec, overseeing clinical development in neurological and immunological diseases, global regulatory affairs, global safety and benefit risk management, global clinical development operations, and biometrics.

Dr. Sandrock is a board-certified neurologist and is Assistant Clinical Professor of Neurology at Harvard Medical School.  His contributions to the literature include peer-reviewed articles on axonal regeneration, synapse formation, neurophysiology, and multiple sclerosis. 

Dr. Sandrock received an MD from Harvard Medical School in Boston, and a PhD in Neurobiology from Harvard University in Cambridge.  He completed an internship in Medicine, a residency and chief residency in Neurology, and a Clinical Fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography) at Massachusetts General Hospital.

- Back to top -

Scott Zamvil, M.D., Ph.D., University of California, San Francisco

Scott S. Zamvil, M.D., Ph.D., is a clinical neurologist and immunologist at the University of California, San Francisco (UCSF) who specializes in the care of patients with multiple sclerosis (MS) and is devoted to developing novel treatments for MS.  His novel research into the use of statins to fight MS has been featured on the cover of Newsweek and reported by the New York Times, CNN, and National Public Radio.  Dr. Zamvil was the Principal Investigator for the first placebo-controlled trial testing a statin drug in multiple sclerosis. In his basic science research, Dr. Zamvil investigates the role of antigen-presenting cells in the activation of T cells.  He has publications in Nature, Nature Medicine, The Journal of Clinical Investigation, The Journal of Experimental Medicine, Annals of Neurology and The Journal of Immunology.

Dr. Zamvil received his M.D. and Ph.D. in Medical Microbiology and Immunology from Stanford University, California, where he trained in internal medicine. He completed a residency in neurology at Brigham and Women's Hospital, Boston, Massachusetts, subsequently joining the Harvard neurology faculty.  In 1994, Dr. Zamvil was named a NMSS Harry Weaver Science Scholar.  Since 1998, he has been on neurology faculty at UCSF where he is Professor of Neurology.  Dr. Zamvil has joint appointments as a faculty member in the Program in Immunology and the Biomedical Sciences Graduate Program.

Dr. Zamvil is on the Editorial Boards of The Journal of Clinical Investigation and Neurotherapeutics, and was previously on the Editorial Board of The Journal of Immunology. His research is funded by the National Multiple Sclerosis Society (NMSS), National Institutes of Health (NIH), Guthy Jackson Charitable Foundation and Maisin Foundation.  Dr. Zamvil served six years on the NMSS Peer Review Research Grant Committee, and currently serves as a Charter Member of the NIH Clinical Neuroimmunology and Brain Tumors (CNBT) grant review committee.

- Back to top -

JOIN US

Accelerate Treatments to MS Patients

Your support will help us deliver a first-in-class myelin repair treatment to multiple sclerosis patients as rapidly as possible. Donations at all levels are critical to achieving this mission.

Donate Now

Keep Updated On Our Progress

Sign Up for Email Updates